ADCT vs GILD
ADCT: ADC Therapeutics develops antibody-drug conjugates (ADCs) targeting hematologic and solid tumors, with its lead product ZYNLONTA commercialized for lymphoma. GILD: A diversified biopharmaceutical company pioneering viral disease treatments, cell therapies, and oncology medicines with a portfolio spanning HIV, hepatitis, and cancer.
Side-by-side fundamentals
| Metric | ADCT | GILD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.24 | $130.34 | |
| Market cap as of 2026-07-23 | $158M | $163.6B | |
| P/E as of 2026-07-23 | n/a | 17.75 | |
| PEG as of 2026-07-23 | n/a | 1.94 | |
| Net margin as of 2026-07-23 | -173.0% | +31.0% | GILD higher |
| Gross margin as of 2026-07-23 | +90.7% | +79.3% | ADCT higher |
| Operating margin as of 2026-07-23 | -149.4% | +34.9% | GILD higher |
| ROE as of 2026-07-23 | -229.2% | +42.2% | GILD higher |
| ROA as of 2026-07-23 | -44.7% | +16.1% | GILD higher |
| Debt / equity as of 2026-07-23 | 9.01 | 0.94 | GILD lower |
| Revenue growth (YoY) as of 2026-07-23 | +4.4% | +3.5% | ADCT higher |
| Revenue CAGR (3y) SEC XBRL | -27.1% | +2.6% | GILD higher |
| Dividend yield as of 2026-07-23 | n/a | +2.5% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 1.83 | 0.34 | |
| 1-year return as of 2026-07-22 close | -59.6% | +18.3% | GILD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.